Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 10/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.53 |
| ▸ | SRC | P12931 | 7/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.53 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.53 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.53 |
| ▸ | AKT1 | P31749 | 3/20 | 0.48 |
| ▸ | AKT2 | P31751 | 3/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1350832 | 0.90 | ADORA1 (0.53) | FGFR1PDGFRBPDGFRASRCEGFR | |
| Trifluoroacetic Acid SCHEMBL1350248 | 0.90 | AKT1 (0.48) | FGFR1PDGFRBPDGFRASRCEGFR | |
| Trifluoroacetic Acid SCHEMBL1351923 | 0.86 | AKT1 (0.49) | FGFR1PDGFRBPDGFRASRCEGFR | |
| Trifluoroacetic Acid SCHEMBL1352465 | 0.83 | AKT1 (0.50) | AKT1AKT2 | |
| SCHEMBL1350251 | 0.83 | AKT1 (0.46) | FGFR1PDGFRBPDGFRASRCEGFR | |
| Trifluoroacetic Acid SCHEMBL1351206 | 0.81 | AKT1 (0.51) | AKT1AKT2 | |
| Trifluoroacetic Acid SCHEMBL1352082 | 0.81 | AKT1 (0.53) | AKT1AKT2 | |
| Trifluoroacetic Acid SCHEMBL1351194 | 0.80 | AKT1 (0.56) | AKT1AKT2 | |
| Trifluoroacetic Acid SCHEMBL1352096 | 0.80 | AKT1 (0.57) | AKT1AKT2 | |
| SCHEMBL1352278 | 0.80 | AKT1 (0.49) | AKT1AKT2ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391623-A1 | INHIBITORS OF AKT ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110288090-A1 | Inhibitors of AKT Activity | MERCK SHARP & DOHME CORP. | 2011-11-24 | — | — | US | disclosed |
| WO-2010088177-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288090-A1 | Inhibitors of AKT Activity | PIK3CD, PIK3CA, PIK3CG | FGFR1 1337/4885PDGFRB 878/4885PDGFRA 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.